|

Mutant KRAS G12V-specific TCR transduced autologous T cells Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Changhai Hospital1

Indications

  • Pancreatic Ductal Adenocarcinoma1
  • Pancreatic Neoplasms1
  • Advanced Cancer1
  • Pancreatic Cancer1
  • Cancer1

Other1 trial

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.